Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx have signed a non-binding MoU for the joint development of an affordable anti-malarial drug. This potential partnership aims to combine Kainomyx's novel drug discovery expertise, Aurigene's integrated drug development capabilities, and Dr. Reddy's commercialization abilities in low and middle-income countries, the US, and Europe.
The collaboration addresses the critical need for effective, affordable, and accessible malaria prevention and treatment, especially in vulnerable populations. With 249 million malaria cases and 608,000 deaths reported in 2022, this initiative aligns with Dr. Reddy's goal of reaching 1.5 billion patients by 2030. The partnership will leverage each company's strengths to accelerate the development of innovative medicines targeting cytoskeletal proteins of parasites, a novel mechanism of action.
Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services e Kainomyx hanno firmato un MoU non vincolante per lo sviluppo congiunto di un farmaco antimalarico accessibile. Questa potenziale collaborazione mira a combinare l'expertise di scoperta di farmaci innovativi di Kainomyx, le capacità integrate di sviluppo di farmaci di Aurigene e le abilità di commercializzazione di Dr. Reddy nei paesi a basso e medio reddito, negli Stati Uniti e in Europa.
La collaborazione risponde all'importante necessità di prevenzione e trattamento della malaria efficaci, accessibili e sostenibili, in particolare per le popolazioni vulnerabili. Con 249 milioni di casi di malaria e 608.000 decessi segnalati nel 2022, questa iniziativa si allinea con l'obiettivo di Dr. Reddy di raggiungere 1,5 miliardi di pazienti entro il 2030. La partnership sfrutterà i punti di forza di ciascuna azienda per accelerare lo sviluppo di medicinali innovativi mirati alle proteine citoscheletriche dei parassiti, un meccanismo d'azione innovativo.
Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services y Kainomyx han firmado un MoU no vinculante para el desarrollo conjunto de un medicamento antipalúdico asequible. Esta asociación potencial busca combinar la experiencia en descubrimiento de fármacos novedosos de Kainomyx, las capacidades integradas de desarrollo de medicamentos de Aurigene y las habilidades de comercialización de Dr. Reddy en países de bajos y medios ingresos, Estados Unidos y Europa.
La colaboración aborda la necesidad crítica de prevención y tratamiento de la malaria que sea efectiva, asequible y accesible, especialmente en poblaciones vulnerables. Con 249 millones de casos de malaria y 608,000 muertes reportadas en 2022, esta iniciativa se alinea con el objetivo de Dr. Reddy de alcanzar a 1.5 mil millones de pacientes para 2030. La asociación aprovechará las fortalezas de cada empresa para acelerar el desarrollo de medicamentos innovadores dirigidos a las proteínas del citoesqueleto de los parásitos, un mecanismo de acción novedoso.
Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, 그리고 Kainomyx는 저렴한 항 말라리아 약물의 공동 개발을 위한 비구속적 양해각서를 체결했습니다. 이 잠재적인 파트너십은 Kainomyx의 혁신적인 약물 발견 전문성, Aurigene의 통합 약물 개발 능력, 그리고 Dr. Reddy의 저소득 및 중간 소득 국가, 미국 및 유럽에서의 상업화 능력을 결합하는 것을 목표로 합니다.
이 협력은 특히 취약한 인구를 위해 효과적이고 저렴하며 접근 가능한 말라리아 예방 및 치료의 긴급한 필요성을 해결합니다. 2022년에 2억 4,900만 건의 말라리아 사례와 60만 8천 건의 사망자가 보고되면서, 이 이니셔티브는 Dr. Reddy의 2030년까지 15억 환자에 도달한다는 목표와 일치합니다. 이 파트너십은 각 회사의 강점을 활용하여 기생충의 세포골격 단백질을 표적으로 하는 혁신적인 의약품 개발을 가속화할 것입니다. 이들은 새로운 작용 기작을 가지고 있습니다.
Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services et Kainomyx ont signé un protocole d'accord non contraignant pour le développement conjoint d'un médicament antipaludique abordable. Ce partenariat potentiel vise à combiner l'expertise de Kainomyx en matière de découverte de médicaments novateurs, les capacités de développement intégré de médicaments d'Aurigene et les compétences de commercialisation de Dr. Reddy dans les pays à revenu faible et intermédiaire, aux États-Unis et en Europe.
Cette collaboration répond à un besoin critique de prévention et de traitement de la malaria qui soit efficace, abordable et accessible, en particulier pour les populations vulnérables. Avec 249 millions de cas de malaria et 608 000 décès rapportés en 2022, cette initiative est en accord avec l'objectif de Dr. Reddy d'atteindre 1,5 milliard de patients d'ici 2030. Le partenariat exploitera les forces de chaque entreprise pour accélérer le développement de médicaments innovants visant les protéines du cytosquelette des parasites, un mécanisme d'action novateur.
Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services und Kainomyx haben ein nicht verbindliches Memorandum of Understanding für die gemeinsame Entwicklung eines erschwinglichen Antimalariamittels unterzeichnet. Diese potenzielle Partnerschaft zielt darauf ab, die neuartigen Wirkstoffentdeckungsfähigkeiten von Kainomyx, die integrierten Arzneimittelentwicklungsfähigkeiten von Aurigene und die Vermarktungsfähigkeiten von Dr. Reddy in einkommensschwachen und mittellosen Ländern, den USA und Europa zu kombinieren.
Die Zusammenarbeit adressiert den dringenden Bedarf an effektiven, erschwinglichen und zugänglichen Malariapräventions- und -behandlungsoptionen, insbesondere für gefährdete Bevölkerungsgruppen. Mit 249 Millionen Malariafällen und 608.000 Todesfällen, die im Jahr 2022 gemeldet wurden, stimmt diese Initiative mit Dr. Reddy's Ziel überein, bis 2030 1,5 Milliarden Patienten zu erreichen. Die Partnerschaft wird die Stärken jedes Unternehmens nutzen, um die Entwicklung innovativer Medikamente zu beschleunigen, die auf Zytoskelettproteine von Parasiten abzielen, einem neuartigen Wirkmechanismus.
- Potential partnership to develop affordable anti-malarial drug
- Combines expertise in drug discovery, development, and commercialization
- Addresses a critical global health issue affecting 249 million people annually
- Targets low and middle-income countries, as well as US and Europe markets
- Novel mechanism of action targeting cytoskeletal proteins of parasites
- Non-binding MoU, subject to signing of a definitive agreement
- Potential challenges in drug development and regulatory approvals
- Competitive landscape in anti-malarial drug market
Insights
This potential partnership for developing an affordable anti-malarial drug is a significant step in global health. The collaboration leverages Kainomyx's novel cytoskeletal protein targeting platform, which could overcome drug resistance issues plaguing current treatments. With
The focus on affordability and accessibility for low and middle-income countries is crucial, as these regions bear the brunt of malaria's impact. However, the success of this venture will depend on the efficacy and safety of the developed drug, as well as its ability to outperform existing treatments. The potential impact on global health could be substantial if the partnership succeeds in bringing a novel, effective and affordable anti-malarial to market.
This partnership aligns with the growing trend of pharmaceutical companies addressing global health challenges in emerging markets. Dr. Reddy's commitment to reaching 1.5 billion patients by 2030 demonstrates a strategic focus on expanding market share in low and middle-income countries. The collaboration could enhance Dr. Reddy's portfolio and reputation in the public health sector.
However, the financial impact remains uncertain at this early stage. The success of this venture depends on factors such as R&D costs, clinical trial outcomes and market acceptance. While the potential market is vast, pricing strategies for affordable drugs in low-income countries may impact profit margins. Investors should monitor the progress of this partnership and its alignment with Dr. Reddy's long-term growth strategy in emerging markets.
While this partnership shows promise for addressing a critical global health issue, its financial implications for Dr. Reddy's are not immediately clear. The company's investment in R&D for this project and potential returns need careful consideration. The focus on affordability may limit profit margins, but could be offset by high volume sales in emerging markets.
Investors should note that this is a long-term initiative with uncertain outcomes. Success could boost Dr. Reddy's revenue and market position in low and middle-income countries, aligning with its 2030 patient reach goal. However, the project carries risks associated with drug development and market acceptance. The financial impact will depend on the final terms of the partnership, development costs and the drug's eventual market performance.
- Malaria is a life-threatening public health issue, particularly in low- and middle-income countries. There is a need for an effective, affordable, and accessible preventive and/or treatment medication. This potential partnership is a step towards this cause
-
This potential partnership aims to bring together Kainomyx’s expertise in novel drug discovery, Aurigene’s capability to conduct integrated drug discovery and development, and Dr. Reddy’s ability to commercialize products in low and middle-income countries, in addition to the US and
Europe - It is a testament to the commitment of involved parties towards promoting global public health and Dr. Reddy’s goal of reaching 1.5 billion patients by 2030
Malaria is a serious health challenge that has a disproportionate prevalence in vulnerable populations of low-income countries. As per WHO, an alarming number of 249 million malaria cases and 608,000 cases of malaria death were reported in year 2022. It has been widely reported that climate change will increase the incidences of such vector-borne diseases1. With this collaboration, the companies intend to drive a comprehensive research and development agenda to leverage their strengths and accelerate the program.
Under the MoU, Kainomyx has agreed to lead the technical strategy and associated aspects for drug discovery and clinical phases, Aurigene has agreed to focus on developing cost-effective and scalable drug chemistry, and while the program evolves, Dr. Reddy’s will bring in its regulatory and market access expertise.
Deepak Sapra, CEO – API and Services, Dr. Reddy’s Laboratories Ltd., said: “Public health and access is a strategic area for us and malaria continues to be a very important disease that needs innovative as well as affordable medicines. The MoU with Kainomyx is a promising step in that direction and towards improving global health outcomes and delivering on Dr. Reddy’s vision to reach 1.5 billion patients by 2030.”
Akhil Ravi, CEO, Aurigene Pharmaceutical Services Ltd., adds, “We are excited to collaborate with Dr. James and the Kainomyx team given their expertise in bringing innovative medicines to market. We share the same vision of addressing global health issues by serving neglected populations.”
James Spudich, Executive Chairman of Kainomyx, states, “new drug discovery for Malaria and other parasitic diseases is essential because drug resistance to existing therapeutics is rapidly developing. Through our decades of work, we have developed a deep understanding of how cytoskeletal proteins work. Cytoskeletal proteins are essential for all living organisms, and we are exploiting this to specifically target the cytoskeleton for treatment of Malaria. I am delighted that in our molecules’ journey to market we will be forming a partnership with Dr. Reddy’s and Aurigene who have demonstrated their experience and expertise through their work in public health.”
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in
About Aurigene: Aurigene, a Dr. Reddy’s Laboratories company, is a global contract research, development, and manufacturing organization (CRDMO) built on the legacy of accelerating innovation and backed by a vast experience in drug discovery, development, and manufacturing of small and large molecules. We offer integrated and standalone services for discovery chemistry, biotherapeutics discovery, discovery biology, development and manufacturing services for clinical phase I-III programs, regulatory submission batches and commercial manufacturing. For more details about Aurigene, please visit www.aurigeneservices.com.
About Kainomyx: Kainomyx Inc. is a
1 https://www.who.int/news-room/fact-sheets/detail/malaria
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information contained herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240820774139/en/
Media Contact:
USHA IYER; ushaiyer@drreddys.com
Source: Dr. Reddy’s Laboratories Ltd.
FAQ
What is the purpose of the partnership between Dr. Reddy's, Aurigene, and Kainomyx?
How many malaria cases were reported in 2022 according to the press release?
What is the novel mechanism of action for the anti-malarial drug being developed?
What is Dr. Reddy's (RDY) patient reach goal mentioned in the press release?
What is the current status of the partnership agreement between Dr. Reddy's, Aurigene, and Kainomyx?
